Pharminent · Daily Brief

November 16, 2026
Regulatory & Approvals

FDA declines to approve Summit’s ivonescimab in lung cancer

The US FDA has declined to approve Summit Therapeutics’ biologics license application for ivonescimab in patients with locally advanced or metastatic non-small cell lung cancer.

Pharmaceutical Technology →

FDA approves AstraZeneca’s Imfinzi with enfortumab vedotin in MIBC

The US FDA approved AstraZeneca’s Imfinzi in combination with enfortumab vedotin for adult patients with muscle-invasive bladder cancer who cannot receive or have refused cisplatin-based chemotherapy.

Pharmaceutical Technology →$AZN

Alexion’s Klygefa approved in US and EU for gMG

AstraZeneca’s Alexion unit won approval in the US and the EU for Klygefa in generalised myasthenia gravis.

Pharmaphorum →$AZN
Business & Finance

Seawolf raises $100M and discloses Sanofi partnership

DNA therapeutics developer Seawolf Therapeutics raised $100 million from backers including Versant, MPM BioImpact, Eli Lilly and Novartis’ venture arm, and disclosed a partnership with Sanofi worth up to $1.2 billion.

BioPharma Dive →$LLY$NVS$SNY

Oyster Therapeutics raises $60M for tau-degrading small molecules

Oyster Therapeutics raised $60 million in a financing that included Eli Lilly; its lead program is a brain-penetrant small molecule that degrades pathological tau associated with Alzheimer’s disease.

MedCity News →$LLY

Get the signal in your inbox

Sign up free →

Pharminent — Competitive Intelligence Suite · Tickers link to Yahoo Finance for reference only. Editorial framings are analysis, not investment advice. © 2026.